

FILE COPY

Copied to RHH + Craig;
forwarded to Dennis + Andre

L. J. McDermott

TELEFAX COMMUNICATION

Fax: 732 739-0713

TO: DR. R. Harris / D. Miller

Re: SANKYO

DATE: June 17, 1998

NUMBER OF PAGES: 2

MESSAGE:

PLS. SEE ATTACHED A RE-GROWN
RESPONSE FROM SANKYO.

Regards,
LARRY

This communication is intended only for the use of the individual or organization to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure. If the actual recipient is not the intended recipient, or an employee or agent responsible for delivering this facsimile to the entity intended recipient, you are hereby notified that any review, disclosure, dissemination, distribution or copying of the attached communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately at the telephone/telefax numbers listed herein.

59 Quai de Valmy

75010, Paris

33 1 42 00 01 28 Phone

33 1 42 00 01 28 Fax



SANKYO CO., LTD.

No. 5-1, Nihonbashi Honcho 3-Chome, Chuo-ku.
Tokyo 103-8426, Japan
Phone: 03-5255-7084 (direct in) Fax: 03-5255-7000

Licensing Department

June 19, 1998

LD No. 10-270Y

Mr. L.J. McDermott
59 Quai de Valmy
75010, Paris
France

Tel: (33) 1 42 00 0128
Fax: (33) 1 42 00 01 28

Dear Mr. McDermott:

Thank you for your facsimile letter of June 10 regarding ADD 2340 17.

We have reviewed and discussed the compound thoroughly.

Unfortunately, we have received a negative reply from our colleagues because of the following reasons:

- 1) the difference of pharmacological doses and maximal safety doses is too small
- 2) the mechanism of action can not be explained only by strychnine-insensitive glycine receptor antagonism.
- 3) the difficulty of clinical trials in Japan for this kind of compound

For the above reasons, we have to decline your proposal for the present time. We greatly appreciate you for giving us the opportunity to review it and look forward to another opportunity in the near future.

Best regards,

Sincerely yours,

Masafumi Yoshimoto, Ph.D.
Director, Licensing Department

MY/kl/yt

4018-02